Industry
Biotechnology
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Loading...
Open
1.07
Mkt cap
311M
Volume
5.2M
High
1.10
P/E Ratio
-6.00
52-wk high
2.10
Low
1.04
Div yield
N/A
52-wk low
0.35
Portfolio Pulse from Benzinga Insights
August 09, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:54 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 10:31 am
Portfolio Pulse from Henry Khederian
August 01, 2024 | 1:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:28 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 6:55 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 9:08 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 9:08 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 10:41 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.